Iranian journal of kidney diseases最新文献

英文中文

Shenqi Pill Mitigates Renal Interstitial Fibrosis Through Weakening Notch1/Jag1 Pathway. 神气丸通过削弱Notch1/Jag1通路缓解肾间质纤维化

IF 0.8 4区医学 Q4 UROLOGY & NEPHROLOGY

Iranian journal of kidney diseases

Pub Date : 2024-05-01 DOI: 10.52547/b56av842

Hongshu Chen, Yuanxiao Yang, Xiaojie Zhou, Yaorong Feng

Introduction: Shenqi pill (SQP) can be used to treat various kidney related diseases, but its exact mechanism of action remains unclear. We intended to analyze the role and mechanism of SQP on renal interstitial fibrosis (RIF).

Methods: After performing unilateral ureteral obstruction (UUO) surgery following the Institutional Animal Care and Use Committee guidelines, all rats were assigned into the sham group, UUO group, UUO + SQP 1.5 g/kg, UUO + SQP 3 g/kg, and UUO + SQP 6 g/kg groups. After treatment with SQP for 4 weeks, the appearance of kidney, serum creatinine (SCr), and blood urea nitrogen (BUN) levels were monitored in each group. The pathological injury, extracellular matrix (ECM), and Notch1 pathway-related protein levels were measured using H&E staining, Masson staining, immunohistochemistry, and Western blot, respectively.

Results: SQP could obviously ameliorate the appearance of the kidney as well as the levels of SCr and BUN in UUO rats (SCr: 67.6 ± 4.64 μM, 59.66 ± 4.96 μM, 48.76 ± 4.44 μM, 40.43 ± 3.02 μM for UUO, low, medium, and high SQP treatment groups; BUN: 9.09 ± 0.97 mM, 7.72 ± 0.61 mM, 5.42 ± 0.42 mM, 4.24 ± 0.34 mM for UUO, low, medium, and high SQP treatment groups; P < .05). SQP also effectively mitigated renal tissue injury in UUO rats (P < .05). Moreover, we uncovered that SQP significantly inhibited Collagen I, α-SMA, Collagen IV, TGF-B1, Notch1, and Jag1 protein expressions in UUO rats kidney (P < .05).

Conclusion: Our data elucidated that SQP can alleviate RIF, and the mechanism may be related to the Notch1/Jag1 pathway. DOI: 10.52547/ijkd.7703.

简介神气丸（SQP）可用于治疗多种肾脏相关疾病，但其确切的作用机制尚不清楚。我们旨在分析神气丸对肾间质纤维化（RIF）的作用和机制：方法：按照动物护理和使用委员会的指导原则进行单侧输尿管梗阻（UUO）手术后，将所有大鼠分为假组、UUO 组、UUO + SQP 1.5 g/kg 组、UUO + SQP 3 g/kg 组和 UUO + SQP 6 g/kg 组。使用 SQP 治疗 4 周后，监测各组的肾脏外观、血清肌酐（SCr）和血尿素氮（BUN）水平。采用H&E染色、Masson染色、免疫组化和Western blot等方法分别检测病理损伤、细胞外基质（ECM）和Notch1通路相关蛋白水平：结果：SQP 能明显改善 UUO 大鼠肾脏的外观以及 SCr 和 BUN 的水平（SCr：UUO、低、中、高 SQP 治疗组的 SCr：67.6 ± 4.64 μM、59.66 ± 4.96 μM、48.76 ± 4.44 μM、40.43 ± 3.02 μM；UUO、低、中、高 SQP 治疗组的 BUN：9.09 ± 0.97 mM、7.72 ± 0.61 mM、5.42 ± 0.42 mM、4.24 ± 0.34 mM；P < .05）。SQP 还能有效减轻 UUO 大鼠的肾组织损伤（P < .05）。此外，我们还发现 SQP 能显著抑制 UUO 大鼠肾脏中胶原 I、α-SMA、胶原 IV、TGF-B1、Notch1 和 Jag1 蛋白的表达（P < .05）：我们的数据阐明了SQP能缓解RIF，其机制可能与Notch1/Jag1通路有关。DOI: 10.52547/ijkd.7703.

{"title":"Shenqi Pill Mitigates Renal Interstitial Fibrosis Through Weakening Notch1/Jag1 Pathway.","authors":"Hongshu Chen, Yuanxiao Yang, Xiaojie Zhou, Yaorong Feng","doi":"10.52547/b56av842","DOIUrl":"10.52547/b56av842","url":null,"abstract":"Introduction: Shenqi pill (SQP) can be used to treat various kidney related diseases, but its exact mechanism of action remains unclear. We intended to analyze the role and mechanism of SQP on renal interstitial fibrosis (RIF).Methods: After performing unilateral ureteral obstruction (UUO) surgery following the Institutional Animal Care and Use Committee guidelines, all rats were assigned into the sham group, UUO group, UUO + SQP 1.5 g/kg, UUO + SQP 3 g/kg, and UUO + SQP 6 g/kg groups. After treatment with SQP for 4 weeks, the appearance of kidney, serum creatinine (SCr), and blood urea nitrogen (BUN) levels were monitored in each group. The pathological injury, extracellular matrix (ECM), and Notch1 pathway-related protein levels were measured using H&E staining, Masson staining, immunohistochemistry, and Western blot, respectively.Results: SQP could obviously ameliorate the appearance of the kidney as well as the levels of SCr and BUN in UUO rats (SCr: 67.6 ± 4.64 μM, 59.66 ± 4.96 μM, 48.76 ± 4.44 μM, 40.43 ± 3.02 μM for UUO, low, medium, and high SQP treatment groups; BUN: 9.09 ± 0.97 mM, 7.72 ± 0.61 mM, 5.42 ± 0.42 mM, 4.24 ± 0.34 mM for UUO, low, medium, and high SQP treatment groups; P < .05). SQP also effectively mitigated renal tissue injury in UUO rats (P < .05). Moreover, we uncovered that SQP significantly inhibited Collagen I, α-SMA, Collagen IV, TGF-B1, Notch1, and Jag1 protein expressions in UUO rats kidney (P < .05).Conclusion: Our data elucidated that SQP can alleviate RIF, and the mechanism may be related to the Notch1/Jag1 pathway. DOI: 10.52547/ijkd.7703.","PeriodicalId":14610,"journal":{"name":"Iranian journal of kidney diseases","volume":"18 3","pages":"159-167"},"PeriodicalIF":0.8,"publicationDate":"2024-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141431965","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Erratum. 勘误。

IF 1.3 4区医学 Q4 UROLOGY & NEPHROLOGY

Iranian journal of kidney diseases

Pub Date : 2024-04-25 DOI: 10.5254/0zev2y05

Admin Admin

No Abstract. DOI: <a href="http://dx.doi.org/10.52547/ijkd.8206" target="_blank">10.52547/ijkd.8206</a>.

无摘要。DOI: <a href="http://dx.doi.org/10.52547/ijkd.8206" target="_blank">10.52547/ijkd.8206</a>.

引用次数: 0

IF 1.3 4区医学 Q4 UROLOGY & NEPHROLOGY

Iranian journal of kidney diseases

Pub Date : 2024-04-25 DOI: 10.5254/dt6zs176

Azin Ghaffari, Mitra Mehrazma, Shahrzad Ossareh

IgG4-related disease (IgG4-RD) is a chronic systemic inflammatory disease, characterized by tissue infiltration of lymphocytes and IgG4-secreting plasma cells, presenting by fibrosis of different tissues, which is usually responsive only to oral steroids therapy. Kidneys are the most commonly involved organs, exhibiting renal insufficiency, tubulointerstitial nephritis, and glomerulonephritis. Here, we describe a patient with acute renal insufficiency who was presented with edema, weakness, anemia and multiple lymphadenopathies. Kidney and lymph node biopsy showed crescentic glomerulonephritis in kidneys and lymphoplasmacytic infiltration in lymph nodes. After a course of treatment with an intravenous pulse of corticosteroid and cyclophosphamide, the patient's symptoms subsided, and kidney function improved. DOI: 10.52547/ijkd.7788.

IgG4 相关疾病（IgG4-RD）是一种慢性全身性炎症性疾病，以淋巴细胞和分泌 IgG4 的浆细胞的组织浸润为特征，表现为不同组织的纤维化，通常只对口服类固醇治疗有反应。肾脏是最常受累的器官，表现为肾功能不全、肾小管间质性肾炎和肾小球肾炎。在此，我们描述了一名急性肾功能不全患者，该患者出现水肿、虚弱、贫血和多发性淋巴结病变。肾脏和淋巴结活检显示，肾脏出现新月体性肾小球肾炎，淋巴结出现淋巴浆细胞浸润。经过一个疗程的皮质类固醇和环磷酰胺静脉脉冲治疗后，患者症状缓解，肾功能改善。DOI: 10.52547/ijkd.7788.

引用次数: 0

Attenuating Renal Interstitial Fibrosis by Shenqi Pill via Reducing Inflammation Response Regulated by NF-κB Pathway In Vitro and In Vivo. 神气丸通过降低体外和体内 NF-κB 通路调控的炎症反应减轻肾间质纤维化

IF 1.3 4区医学 Q4 UROLOGY & NEPHROLOGY

Iranian journal of kidney diseases

Pub Date : 2024-04-25 DOI: 10.5254/kv5ap920

Hongshu Chen, Yuanxiao Yang, Xiaojie Zhou, Yaorong Feng

One of the most significant clinical features of chronic kidney disease is renal interstitial fibrosis (RIF). This study aimed to investigate the role and mechanism of Shenqi Pill (SQP) on RIF.

慢性肾脏病最重要的临床特征之一是肾间质纤维化（RIF）。本研究旨在探讨神气丸（SQP）对肾间质纤维化的作用和机制。

引用次数: 0

Risk Factors and Clinical Characterization of Cardiovascularand Cerebrovascular Events in Elderly Hemodialysis Patients. 老年血液透析患者心脑血管事件的风险因素和临床特征。

IF 1.3 4区医学 Q4 UROLOGY & NEPHROLOGY

Iranian journal of kidney diseases

Pub Date : 2024-04-25 DOI: 10.5254/r2vqgm28

Wei Liu, Hong Ze Wang, Ying Shi, Weiqiang Shen, Mingyan Dai

The purpose of this study was to assess the risk factors and clinical characteristics of cardiovascular and cerebrovascular events in elderly hemodialysis patients.

本研究旨在评估老年血液透析患者发生心脑血管事件的风险因素和临床特征。

引用次数: 0

Conceptual Approach to Body Fluids and Edema, Education Determines Clinical Outcomes in Heart Failure. 体液和水肿的概念方法，教育决定心力衰竭的临床结果。

IF 1.3 4区医学 Q4 UROLOGY & NEPHROLOGY

Iranian journal of kidney diseases

Pub Date : 2024-04-25 DOI: 10.5254/1aytkx77

Mohammad A Shafiee, Amireza Goli, Pouyan Shaker, Vishal Sharma, Yasmin Shahideh, Khrystyna Maryniak, Behrooz Broumand

In this brief communication, we reemphasize the importance of critical thinking in clinical practice using the example of edema. The common practice of thinking and inquiry by practicing clinicians has beneficial implications for healthcare by improving outcomes and patient care while alleviating the burden of misconceptions in practice. We provide an in-depth and interactive investigation of physiological concepts as a foundation for understanding body fluid dynamics. Finally, we offer a new classification of symptoms of heart failure. DOI: 10.52547/ijkd.8171.

在这篇简短的通讯中，我们以水肿为例，再次强调批判性思维在临床实践中的重要性。临床医生普遍的思考和探究实践对医疗保健具有有益的影响，既能改善治疗效果和患者护理，又能减轻实践中的误解负担。我们对生理概念进行了深入的互动式探究，以此作为理解体液动力学的基础。最后，我们对心力衰竭的症状进行了新的分类。DOI: 10.52547/ijkd.8171.

引用次数: 0

Microvesicles from Mesenchymal Stem Cells Overexpressing MiR-34a Ameliorate Renal Fibrosis In Vivo. 过表达 MiR-34a 的间充质干细胞微囊可改善体内肾脏纤维化

IF 1.3 4区医学 Q4 UROLOGY & NEPHROLOGY

Iranian journal of kidney diseases

Pub Date : 2024-04-25 DOI: 10.5254/s9bdqs74

Yan Wang, Ping Hu, Yangping Li, Ruijuan Dong, Juan He

We recently discovered that microvesicles (MVs) derived from mesenchymal stem cells (MSCs) overexpressing miRNA-34a can alleviate experimental kidney injury in mice. In this study, we further explored the effects of miR34a-MV on renal fibrosis in the unilateral ureteral obstruction (UUO) models. Methods. Bone marrow MSCs were modified by lentiviruses overexpressing miR-34a, and MVs were collected from the supernatants of MSCs. C57BL6/J mice were divided into control, unilateral ureteral obstruction (UUO), UUO + MV, UUO + miR-34aMV and UUO + miR-34a-inhibitor-MV groups. MVs were injected to mice after surgery. The mice were then euthanized on day 7 and 14 of modeling, and renal tissues were collected for further analyses by Hematoxylin and eosin, Masson's trichrome, and Immunohistochemical (IHC) staining. Results. The UUO + MV group exhibited a significantly reduced degree of renal interstitial fibrosis with inflammatory cell infiltration, tubular epithelial cell atrophy, and vacuole degeneration compared with the UUO group. Surprisingly, overexpressing miR-34a enhanced these effects of MSC-MV on the UUO mice. Conclusion. Our study demonstrates that miR34a further enhances the effects of MSC-MV on renal fibrosis in mice through the regulation of epithelial-to-mesenchymal transition (EMT) and Notch pathway. miR-34a may be a candidate molecular therapeutic target for the treatment of renal fibrosis. DOI: 10.52547/ijkd.7673.

我们最近发现，间充质干细胞（MSCs）过度表达 miRNA-34a 后产生的微囊泡（MVs）可减轻小鼠的实验性肾损伤。在本研究中，我们进一步探讨了 miR34a-MV 对单侧输尿管梗阻（UUO）模型肾纤维化的影响。研究方法用过表达 miR-34a 的慢病毒修饰骨髓间充质干细胞，从间充质干细胞上清液中收集 MV。将 C57BL6/J 小鼠分为对照组、单侧输尿管梗阻（UUO）组、UUO + MV 组、UUO + miR-34aMV 组和 UUO + miR-34a 抑制剂-MV 组。手术后向小鼠注射 MV。然后在建模第 7 天和第 14 天对小鼠实施安乐死，并收集肾组织，通过苏木精和伊红、Masson 三色和免疫组织化学（IHC）染色进行进一步分析。结果与 UUO 组相比，UUO + MV 组的肾间质纤维化程度明显减轻，并伴有炎性细胞浸润、肾小管上皮细胞萎缩和空泡变性。令人惊讶的是，过表达 miR-34a 能增强间充质干细胞-间充质干细胞对 UUO 小鼠的上述作用。结论我们的研究表明，miR34a通过调控上皮细胞向间质转化（EMT）和Notch通路，进一步增强了间充质干细胞-MV对小鼠肾脏纤维化的影响，miR-34a可能是治疗肾脏纤维化的候选分子治疗靶点。DOI: 10.52547/ijkd.7673.

{"title":"Microvesicles from Mesenchymal Stem Cells Overexpressing MiR-34a Ameliorate Renal Fibrosis In Vivo.","authors":"Yan Wang, Ping Hu, Yangping Li, Ruijuan Dong, Juan He","doi":"10.5254/s9bdqs74","DOIUrl":"https://doi.org/10.5254/s9bdqs74","url":null,"abstract":"We recently discovered that microvesicles (MVs) derived from mesenchymal stem cells (MSCs) overexpressing miRNA-34a can alleviate experimental kidney injury in mice. In this study, we further explored the effects of miR34a-MV on renal fibrosis in the unilateral ureteral obstruction (UUO) models. Methods. Bone marrow MSCs were modified by lentiviruses overexpressing miR-34a, and MVs were collected from the supernatants of MSCs. C57BL6/J mice were divided into control, unilateral ureteral obstruction (UUO), UUO + MV, UUO + miR-34aMV and UUO + miR-34a-inhibitor-MV groups. MVs were injected to mice after surgery. The mice were then euthanized on day 7 and 14 of modeling, and renal tissues were collected for further analyses by Hematoxylin and eosin, Masson's trichrome, and Immunohistochemical (IHC) staining. Results. The UUO + MV group exhibited a significantly reduced degree of renal interstitial fibrosis with inflammatory cell infiltration, tubular epithelial cell atrophy, and vacuole degeneration compared with the UUO group. Surprisingly, overexpressing miR-34a enhanced these effects of MSC-MV on the UUO mice. Conclusion. Our study demonstrates that miR34a further enhances the effects of MSC-MV on renal fibrosis in mice through the regulation of epithelial-to-mesenchymal transition (EMT) and Notch pathway. miR-34a may be a candidate molecular therapeutic target for the treatment of renal fibrosis. DOI: 10.52547/ijkd.7673.","PeriodicalId":14610,"journal":{"name":"Iranian journal of kidney diseases","volume":"9 1","pages":""},"PeriodicalIF":1.3,"publicationDate":"2024-04-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140801461","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Mind the Gap in Kidney Care: Translating What We Know Into What We Do. 关注肾脏护理中的差距：将我们的知识转化为我们的行动。

IF 1.3 4区医学 Q4 UROLOGY & NEPHROLOGY

Iranian journal of kidney diseases

Pub Date : 2024-04-25 DOI: 10.5254/sqbbj216

Valerie A Luyckx, Katherine R Tuttle, Dina Abdellatif, Ricardo Correa-Rotter, Winston W S Fung, Agnès Haris, Li-Li Hsiao, Makram Khalife, Latha A Kumaraswami, Fiona Loud, Vasundhara Raghavan, Stefanos Roumeliotis, Marianella Sierra, Ifeoma Ulasi, Bill Wang, Siu-Fai Lui, Vassilios Liakopoulos, Alessandro Balducci, Or The World Kidney Day Joint Steering Committee

Historically, it takes an average of 17 years to move new treatments from clinical evidence to daily practice. Given the highly effective treatments now available to prevent or delay kidney disease onset and progression, this is far too long. The time is now to narrow the gap between what we know and what we do. Clear guidelines exist for the prevention and management of common risk factors for kidney disease, such as hypertension and diabetes, but only a fraction of people with these conditions worldwide are diagnosed, and even fewer are treated to target. Similarly, the vast majority of people living with kidney disease are unaware of their condition, because in the early stages it is often silent. Even among patients who have been diagnosed, many do not receive appropriate treatment for kidney disease. Considering the serious consequences of kidney disease progression, kidney failure, or death, it is imperative that treatments are initiated early and appropriately. Opportunities to diagnose and treat kidney disease early must be maximized beginning at the primary care level. Many systematic barriers exist, ranging from patient to clinician to health systems to societal factors. To preserve and improve kidney health for everyone everywhere, each of these barriers must be acknowledged so that sustainable solutions are developed and implemented without further delay. DOI: 10.52547/ijkd.8216.

从历史上看，新疗法从临床证据转化为日常实践平均需要 17 年的时间。鉴于目前已有的高效疗法可以预防或延缓肾病的发生和发展，这个时间太长了。现在是缩小我们所知道的与我们所做的之间差距的时候了。对于高血压和糖尿病等肾脏病常见风险因素的预防和管理，已有明确的指导方针，但全世界只有一小部分肾脏病患者被确诊，接受目标治疗的患者则更少。同样，绝大多数肾病患者都不知道自己的病情，因为肾病在早期往往是无声无息的。即使在已经确诊的患者中，许多人也没有接受适当的肾病治疗。考虑到肾病恶化、肾衰竭或死亡的严重后果，必须及早开始适当的治疗。必须从初级保健开始，最大限度地利用早期诊断和治疗肾病的机会。从患者到临床医生，从医疗系统到社会因素，存在着许多系统性障碍。为了维护和改善世界各地每个人的肾脏健康，必须认识到这些障碍中的每一个，以便制定和实施可持续的解决方案，不再拖延。DOI: 10.52547/ijkd.8216.

{"title":"Mind the Gap in Kidney Care: Translating What We Know Into What We Do.","authors":"Valerie A Luyckx, Katherine R Tuttle, Dina Abdellatif, Ricardo Correa-Rotter, Winston W S Fung, Agnès Haris, Li-Li Hsiao, Makram Khalife, Latha A Kumaraswami, Fiona Loud, Vasundhara Raghavan, Stefanos Roumeliotis, Marianella Sierra, Ifeoma Ulasi, Bill Wang, Siu-Fai Lui, Vassilios Liakopoulos, Alessandro Balducci, Or The World Kidney Day Joint Steering Committee","doi":"10.5254/sqbbj216","DOIUrl":"https://doi.org/10.5254/sqbbj216","url":null,"abstract":"Historically, it takes an average of 17 years to move new treatments from clinical evidence to daily practice. Given the highly effective treatments now available to prevent or delay kidney disease onset and progression, this is far too long. The time is now to narrow the gap between what we know and what we do. Clear guidelines exist for the prevention and management of common risk factors for kidney disease, such as hypertension and diabetes, but only a fraction of people with these conditions worldwide are diagnosed, and even fewer are treated to target. Similarly, the vast majority of people living with kidney disease are unaware of their condition, because in the early stages it is often silent. Even among patients who have been diagnosed, many do not receive appropriate treatment for kidney disease. Considering the serious consequences of kidney disease progression, kidney failure, or death, it is imperative that treatments are initiated early and appropriately. Opportunities to diagnose and treat kidney disease early must be maximized beginning at the primary care level. Many systematic barriers exist, ranging from patient to clinician to health systems to societal factors. To preserve and improve kidney health for everyone everywhere, each of these barriers must be acknowledged so that sustainable solutions are developed and implemented without further delay. DOI: 10.52547/ijkd.8216.","PeriodicalId":14610,"journal":{"name":"Iranian journal of kidney diseases","volume":"50 1","pages":""},"PeriodicalIF":1.3,"publicationDate":"2024-04-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140806280","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Risk Factors Analysis of AKI in Patients with Primary Non-small Cell Lung Cancer Treated with PD-1/PD-L1 Inhibitor. PD-1/PD-L1抑制剂治疗的原发性非小细胞肺癌患者发生AKI的风险因素分析

IF 1.3 4区医学 Q4 UROLOGY & NEPHROLOGY

Iranian journal of kidney diseases

Pub Date : 2024-04-25 DOI: 10.5254/0n3xpz60

Jiong-Ming Ying, Feng Yan

To investigate the risk factors of Programmed Cell Death Protein 1 (PD-1), Programmed Cell Death Ligand 1(PD-L1) inhibitor associated acute kidney injury (AKI) in patients with primary non-small cell lung cancer (NSCLC) and construct a predictive model.

研究原发性非小细胞肺癌（NSCLC）患者中程序性细胞死亡蛋白1（PD-1）、程序性细胞死亡配体1（PD-L1）抑制剂相关急性肾损伤（AKI）的风险因素，并构建预测模型。

引用次数: 0

Correlation Between the 8-hydroxy-2'-deoxyguanosine Level in the Peritoneal Solution of Patients Undergoing Peritoneal Dialysis and the Peritoneal Equilibration Test, Kt/V, Ferritin, and Albumin Levels. 腹膜透析患者腹腔液中 8- 羟基-2'-脱氧鸟苷水平与腹膜平衡试验、Kt/V、铁蛋白和白蛋白水平之间的相关性。

IF 1.3 4区医学 Q4 UROLOGY & NEPHROLOGY

Iranian journal of kidney diseases

Pub Date : 2024-04-25 DOI: 10.5254/fte08z03

Hadi Khanifar, Leila Mahmoodnia

Peritoneal dialysis (PD) is an effective treatment modality for advanced kidney failure, offering patients a significant degree of independence. However, the long-term use of PD is limited due to the degeneration of the peritoneal membrane, resulting in reduced dialysis adequacy. Evaluating the peritoneal membrane condition in patients with advanced kidney failure who are undergoing PD is challenging with existing methods. Therefore, this study aimed to investigate the correlation between 8-hydroxy-2'-deoxyguanosine (8OHDG) levels in the peritoneal solution of patients undergoing PD and various factors, such as peritoneal equilibration test (PET), dialysis adequacy (Kt/V), underlying diseases, serum ferritin, and albumin levels. 8OHDG is a sensitive marker of oxidative stress caused by DNA damage.

腹膜透析（PD）是晚期肾衰竭的一种有效治疗方式，可为患者提供很大程度的独立性。然而，由于腹膜退化导致透析充分性降低，腹膜透析的长期使用受到限制。使用现有方法评估接受腹膜透析的晚期肾衰竭患者的腹膜状况具有挑战性。因此，本研究旨在探讨腹膜透析患者腹腔溶液中 8- 羟基-2'-脱氧鸟苷（8OHDG）水平与腹膜平衡试验（PET）、透析充分性（Kt/V）、基础疾病、血清铁蛋白和白蛋白水平等各种因素之间的相关性。8OHDG 是 DNA 损伤导致氧化应激的敏感标记。

引用次数: 0

首页上一页

下一页尾页

类型

全部化学•材料生命科学医学物理工程技术环境•农林材料科学地球科学法学管理学化学环境科学与生态学计算机科学教育学经济学农林科学人文科学生物学数学物理与天体物理心理学综合性期刊其他工业工程理学历史学农学文学信息工程

数据库

全部 ACS Publications Elsevier ieeexplore Springer The Royal Society of Chemistry Wiley

期刊

Iranian journal of kidney diseases

全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.

﹀